Harsaul Foundation - 19 Oct 2023 Form 4 Insider Report for RVL Pharmaceuticals plc

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 19 Oct 2023
Net transaction value: -$580,147
SEC form: 4
Accepted by SEC: 23 Oct 2023, 16:23:52 UTC
Prior SEC filing: 20 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/CAMILO A. MENDEZ CHONG, Harsaul Foundation, by Dirserv Inc., Foundation Council Member, By: Camilo A. Mendez Chong

Key filing fact

Harsaul Foundation filed Form 4 for RVL Pharmaceuticals plc on 23 Oct 2023.

Key facts

This page summarizes Harsaul Foundation's Form 4 filing for RVL Pharmaceuticals plc.
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 23 Oct 2023, 16:23.

Change

Previous filing in this sequence was filed on 20 Oct 2023.
Current net transaction value: -$580,147.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVLP transaction

Ordinary Shares

Sale

Transaction value: $431,669
Shares: -9,363,760
Change %: -49%
Price: $0.0461
Shares after: 9,700,000
Date: 19 Oct 2023
Ownership: By Self as indirect owner of Altchem Limited
Footnotes: F1, F2

RVLP transaction

Ordinary Shares

Sale

Transaction value: $148,478
Shares: -4,758,899
Change %: -49%
Price: $0.0312
Shares after: 4,941,101
Date: 20 Oct 2023
Ownership: By Self as indirect owner of Altchem Limited
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Harsaul Foundation is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 is the average execution price. These shares were sold in multiple transactions at prices ranging from $0.0400 to $0.0580, inclusive. The reporting person undertakes to provide RVL Pharmaceuticals plc, any security holder of RVL Pharmaceuticals plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

Represents shares of the Issuer held by Altchem Limited. Harsaul Foundation is the indirect owner of Altchem Limited. As a result, Harsaul Foundation may be deemed to share voting and investment power with respect to the shares held by Altchem Limited.

Footnote F3

The price reported in Column 4 is the average execution price. These shares were sold in multiple transactions at prices ranging from $0.0300 to $0.0373, inclusive. The reporting person undertakes to provide RVL Pharmaceuticals plc, any security holder of RVL Pharmaceuticals plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.